Opzelura Ruxolitinib Cream In Pakistan
Opzelura (Ruxolitinib) Cream 1.5% is a prescription topical medication used to treat certain inflammatory skin conditions. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors and is approved for mild to moderate atopic dermatitis (eczema) as well as nonsegmental vitiligo in adults and eligible children. The cream is applied directly to affected skin to help reduce inflammation, itching, and rash in eczema, and to support repigmentation in vitiligo.
Key Benefits:
Opzelura Cream may offer the following clinical benefits when used as prescribed:
Reduces Inflammation and Itching — Helps relieve signs and symptoms of mild to moderate eczema by targeting underlying inflammatory pathways in the skin.
Supports Repigmentation — In vitiligo, Opzelura is the first FDA?approved topical treatment aimed at helping restore skin pigment in depigmented patches.
Steroid?Free Treatment Option — Provides an alternative to topical corticosteroids and other conventional therapies for eczema and vitiligo.
Topical, Targeted Action — Designed to act directly on affected areas with limited systemic absorption when used correctly.
How It Works:
Opzelura contains ruxolitinib, which works by inhibiting JAK1 and JAK2 enzymes — critical components of the JAK?STAT signaling pathway that regulate immune responses and inflammation:
Blocks inflammatory signals: By inhibiting JAK enzymes in skin cells, Opzelura reduces the activity of pro?inflammatory cytokines that drive eczema symptoms like redness, rash, and itch.
Modulates immune activity in vitiligo: In vitiligo, immune cells attack pigment?producing melanocytes. Ruxolitinib’s JAK inhibition helps calm this immune response, which may allow melanocytes to repopulate and restore pigment over time.
How to Use:
Follow your healthcare provider’s instructions precisely. General usage guidelines include:
Apply a thin layer of Opzelura Cream twice daily to affected areas.
For atopic dermatitis: Apply on areas of mild to moderate eczema — treatment may be stopped once symptoms such as itching, redness, and rash improve. Do not use more than one 60?g tube per week for ages 12?years and older.
For nonsegmental vitiligo: Apply similarly to depigmented patches twice daily as prescribed, up to a defined body surface area (commonly up to 10?%).
Topical use only: Do not apply inside the eyes, mouth, or genital areas, and avoid occlusive bandages that seal the cream under the skin.
Wash hands after application unless the treated area is the hands.
If symptoms do not improve after the recommended period (often ~8?weeks for eczema), consult your healthcare provider.
